Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.64 |
| ▸ | PAM | P19021 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | PRKCA | P17252 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.49 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethyl Acetate SCHEMBL756143 | 1.00 | DGKA (0.64) | DGKAPAMLMNAALDH1A1HSD17B10 | |
| Hexane SCHEMBL19611429 | 1.00 | DGKA (0.64) | DGKAPAMLMNAALDH1A1HSD17B10 | |
| Ethyl Acetate SCHEMBL1777438 | 1.00 | DGKA (0.64) | DGKAPAMLMNAALDH1A1HSD17B10 | |
| Ethyl Acetate SCHEMBL31373773 | 1.00 | DGKA (0.64) | DGKAPAMLMNAALDH1A1HSD17B10 | |
| Ethyl Acetate SCHEMBL11889416 | 0.98 | DGKA (0.62) | DGKAPAMLMNAALDH1A1HSD17B10 | |
| Ethyl Acetate SCHEMBL27394742 | 0.98 | DGKA (0.61) | DGKAPAMLMNAALDH1A1HSD17B10 | |
| Ethyl Acetate SCHEMBL3483756 | 0.93 | DGKA (0.56) | DGKAPAMLMNAALDH1A1HSD17B10 | |
| Ethyl Acetate SCHEMBL4168022 | 0.93 | DGKA (0.56) | DGKAPAMLMNAALDH1A1HSD17B10 | |
| Ethyl Acetate SCHEMBL3310609 | 0.93 | DGKA (0.56) | DGKAPAMLMNAALDH1A1HSD17B10 | |
| Acetone SCHEMBL1868300 | 0.92 | DGKA (0.69) | DGKAPAMLMNAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111918881-B | Novel photocrosslinkable alginic acid derivative | 持田制药株式会社 | 2022-08-12 | — | — | CN | disclosed |
| CN-111868096-B | Reactive alginic acid derivatives | 持田制药株式会社 | 2022-06-17 | — | — | CN | disclosed |
| CN-114521199-A | Novel cross-linked alginic acid structure | 持田制药株式会社 | 2022-05-20 | — | — | CN | disclosed |
| CN-111918881-A | Novel photocrosslinkable alginic acid derivative | 持田制药株式会社 | 2020-11-10 | — | — | CN | disclosed |
| CN-111868096-A | Novel reactive alginic acid derivative | 持田制药株式会社 | 2020-10-30 | — | — | CN | disclosed |
| CN-110891951-A | Compound (I) | 谢菲尔德大学 | 2020-03-17 | — | — | CN | disclosed |
| EP-2262508-B1 | SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | BIOELECTRON TECH CORP (US) | 2018-10-03 | — | — | EP | disclosed |
| US-9090576-B2 | 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases | EDISON PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140329860-A1 | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | EDISON PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-8716527-B2 | 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases | EDISON PHARMACEUTICALS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-7384937-B2 | Fused heterocyclic compounds and use thereof | BRISTOL-MYERS SQUIBB CO. (US) | 2008-06-10 | — | — | US | disclosed |
| US-7141611-B2 | High molecular weight primary aliphatic alcohols obtained from natural products and uses thereof | WYETH (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1390331-A4 | HIGH MOLECULAR WEIGHT PRIMARY ALIPHATIC ALCOHOLS OBTAINED FROM NATURAL PRODUCTS AND USES THEREOF | WYETH CORP (US) | 2006-01-11 | — | — | EP | disclosed |
| CN-1522239-A | High molecular weight primary aliphatic alcohols obtained from natural products and uses thereof | 豪泽公司 | 2004-08-18 | — | — | CN | disclosed |
| US-20040142945-A1 | Fused heterocyclic compounds and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-22 | — | — | US | disclosed |
| EP-1390331-A1 | HIGH MOLECULAR WEIGHT PRIMARY ALIPHATIC ALCOHOLS OBTAINED FROM NATURAL PRODUCTS AND USES THEREOF | Hauser, Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20040019119-A1 | High molecular weight primary aliphatic alcohols obtained from natural products and uses thereof | WYETH LLC | 2004-01-29 | — | — | US | disclosed |
| US-6596776-B2 | Subjecting a natural product starting material containing primary aliphatic alcohols to liquid extraction with a liquid organic extractant in which alcohols are soluble; recovering alcohol mixture | HAUSER, INC. | 2003-07-22 | — | — | US | disclosed |
| US-20030096876-A1 | High molecular weight primary aliphatic alcohols obtained from natural products and uses thereof | WYETH LLC | 2003-05-22 | — | — | US | disclosed |
| WO-2002088060-A1 | HIGH MOLECULAR WEIGHT PRIMARY ALIPHATIC ALCOHOLS OBTAINED FROM NATURAL PRODUCTS AND USES THEREOF | HAUSER, INC. (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329860-A1 | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | NQO1, TXNRD2, MT-ND2 | DGKA 1921/4885PAM 4354/4885LMNA 1369/4885 |
| US-20040142945-A1 | Fused heterocyclic compounds and use thereof | MCL1, NFATC1, BCR | DGKA 1539/4885PAM 2613/4885LMNA 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.